



## Immune Ontogeny and Vaccination in Early Life

Guest Editors:

### Dr. Nabila Seddiki

Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases, UMR1184, IDMIT Department, Université Paris-Saclay, Inserm, CEA, 92265 Fontenay-aux-Roses, France

### Prof. Dr. Roger Le Grand

Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases, UMR1184, IDMIT Department, Université Paris-Saclay, Inserm, CEA, France

Deadline for manuscript submissions:

**closed (10 February 2021)**

### Message from the Guest Editors

Dear Colleagues,

The development of the immune system needs a number of changes that occur during the first years of life. The neonatal immune system is exposed to a large number of previously unseen antigens. The field is still lacking a good animal model to get insights into immune ontogeny in early life and development of immune-mediated diseases later in life. We are currently establishing a pediatric immunology program (PIP) where the NHP will be essential and central to developing comprehensive studies that will explore immune ontogeny, microbiome, vaccination, transfer of maternal immunology, system immunology, and serology.

The goal of this Research Topic is to gather several known experts in the field of pediatric immunology, infectious diseases, and vaccinology to give an update on their latest research studies that are relevant to early life newborns and immune-mediated diseases later in life, and to develop a method to use the NHP model in the most comprehensive way to address important/remaining questions in the field.

Dr. Nabila Seddiki  
Prof. Dr. Roger Le Grand  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)